Charles River Laboratories International, Inc. (CRL): Total Liabilities
$3.92B
As of 2025-12-27
$4.64B
As of 2026-06-27
-5.0%
3-year compound annual growth
+3.2%
5-year compound annual growth
+11.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $3.92B | -2.4% | 2026-02-18, Balance as of period end |
| 2024-12-28 | $4.02B | -11.4% | 2026-02-18, Balance as of period end |
| 2023-12-30 | $4.54B | -0.9% | 2025-02-19, Balance as of period end |
| 2022-12-31 | $4.58B | +3.3% | 2024-02-14, Balance as of period end |
| 2021-12-25 | $4.43B | +32.4% | 2023-02-22, Balance as of period end |
| 2020-12-26 | $3.35B | +10.6% | 2022-02-16, Balance as of period end |
| 2019-12-28 | $3.03B | +20.2% | 2021-02-17, Balance as of period end |
| 2018-12-29 | $2.52B | +34.9% | 2020-02-11, Balance as of period end |
| 2017-12-30 | $1.87B | +0.4% | 2019-02-13, Balance as of period end |
| 2016-12-31 | $1.86B | +42.6% | 2018-02-13, Balance as of period end |
| 2015-12-26 | $1.30B | +11.7% | 2017-02-14, Balance as of period end |
| 2014-12-27 | $1.17B | n/c | 2016-02-12, Balance as of period end |
| 2013-12-28 | $968.10M | n/c | 2015-02-17, Balance as of period end |
| 2012-12-29 | $983.14M | -4.6% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $1.03B | -1.3% | 2013-02-27, Balance as of period end |
| 2010-12-25 | $1.04B | +25.8% | 2012-02-27, Balance as of period end |
| 2009-12-26 | $830.27M | n/a | 2011-02-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.92B | -2.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.79B | -10.3% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $1.52B | +18.9% |
| Icon PLC (ICLR) | 2025-12-31 | $7.08B | -1.6% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $23.31B | +11.9% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $33.89M | -10.7% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $33.50M | -8.1% |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗